MetrioPharm AG announces capital increase

MetrioPharm AG / Capital Increase

04.03.2010 07:45

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this
announcement.

---------------------------------------------------------------------------

MetrioPharm AG announces capital increase

+++ Issue of 3,000,000 new shares to strategic investors
+++ Gross proceeds of 750,000 Euros
+++ Opportunity of for additional patent applications

Zurich, 4th March 2010: The governing board and management of MetrioPharm
AG (WKN: A0YD9Q; ISIN: CH0107076744) announce the increase of the share
capital of the company in cash according to a decision of an extraordinary
general meeting of September 30th 2009. The issue of 3,000,000 new
registered shares with a nominal value of CHF 0.20 increases the share
capital of the company from CHF 8,000,000 by CHF 600,000 to CHF 8,600,000.
The preemptive rights of shareholders were excluded. The new shares were
subscribed by a group of strategic investors who increased their share in
MetrioPharm AG to approximately 7 percent. The shares were issued for a
price corresponding to the current market price. MetrioPharm AG will
receive gross proceeds of 750,000 Euros.

Decisive for the participation of the new investors were the advances with
several pipeline products of the company. The MP1000 development pipeline
with its lead substance MP1021 as well as the class of oxirane carboxylic
acids with its lead substance MP2070/Etomoxir reached several important
development milestones earlier than originally projected. In addition, new
scientific results open up the possibility for MetrioPharm to file
additional patents. This can lead to a substantial increase in the value of
the company's drug pipeline.

'Our collaboration with several universities and renowned scientific
institutes like the Helmholtz-Center for Infection Research has revealed a
number of new therapeutic uses for our MP1000 pipeline and the oxirane
carboxylic acids', said Dr. Wolfgang Brysch, president of the governing
board of MetrioPharm AG. 'With the proceeds from the capital increase, we
want to advance these new results into additional patents and pipeline
products.'

Based on the statutes of MetrioPharm AG the governing board is authorized
to increase the share capital by a maximum of CHF 4,000,000 at any time
until the 30th of September 2011. For this capital increase up to
20,000,000 fully liberated registered shares with a nominal value of CHF
0.20 may be issued.


About METRIOPHARM AG:
MetrioPharm AG is a biotechnology company that specializes in the
development and registration of small-molecular drugs which are in an
advanced stage of development. Generally positive proof-of-efficacy data in
humans exist for the company's pipeline products. Lead substances are the
immunomodulator MP1021 for the treatment of severe infectious and
inflammatory diseases and MP2070/Etomoxir for the treatment of chronic
heart failure.

Company Contact:
MetrioPharm AG
Neuendorfstrasse 20B
16761 Hennigsdorf
www.metriopharm.com
T. +49 (0) 3302 20 234 02
F. +49 (0) 3302 20 234 99
info@metriopharm.com

Investor Relations Contact:
GFEI Aktiengesellschaft
Hamburger Allee 26-28
60486 Frankfurt am Main
www.gfei.de
T. +49 (0) 69 743 037 00
F. +49 (0) 69 743 037 22
metriopharm@gfei.de




04.03.2010 Ad hoc announcement, Financial News and Media Release
distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------